Related Experiment Video
Updated: May 24, 2026
07:49
Characterize Disease-related Mutants of RAF Family Kinases by Using a Set of Practical and Feasible Methods
Published on: July 17, 2019
The RAF inhibitor paradox revisited
Adrienne D Cox1, Channing J Der
1Department of Radiation Oncology, Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599, USA. adricox@med.unc.edu
Cancer Cell
|February 21, 2012
Summary
Vemurafenib, a RAF kinase inhibitor, shows promise for BRAF-mutant melanoma, exemplifying personalized medicine. However, this targeted therapy approach has revealed unforeseen challenges in clinical application.
Area of Science:
- Oncology
- Molecular Biology
- Pharmacology
Background:
- Metastatic melanoma with BRAF mutations presents a significant clinical challenge.
- Targeted therapies, such as RAF protein kinase inhibitors, have emerged as a promising treatment strategy.
- Vemurafenib, a RAF inhibitor, has demonstrated success in treating BRAF-mutant melanoma, highlighting the potential of personalized medicine.
Purpose of the Study:
- To evaluate the clinical efficacy and challenges associated with vemurafenib in treating BRAF-mutant metastatic melanoma.
- To explore the broader implications of signal transduction-targeted therapies in cancer treatment.
Main Methods:
- Clinical study evaluating vemurafenib treatment in patients with BRAF-mutant metastatic melanoma.
- Analysis of treatment outcomes, including efficacy and adverse events.
- Investigation into the mechanisms underlying treatment response and resistance.
Main Results:
- Vemurafenib demonstrated success in a subset of patients with BRAF-mutant metastatic melanoma.
- The study identified unexpected challenges and limitations in the application of this targeted therapy.
- These findings underscore the complexity of signal transduction-targeted therapies.
Conclusions:
- While vemurafenib represents a significant advancement in personalized medicine for melanoma, its application is not without complexities.
- Further research is needed to overcome the identified pitfalls and optimize the use of signal transduction-targeted therapies.
- The study emphasizes the need for a comprehensive understanding of targeted therapy mechanisms and patient responses.
Related Concept Videos
01:25Antihypertensive Drugs: Direct Renin Inhibitors
The renin-angiotensin-aldosterone system (RAAS) is an intricate physiological pathway involving numerous enzymes and hormones, including renin, angiotensin-converting enzyme (ACE), angiotensin I and II, and aldosterone. Imbalances within this system increase the production of angiotensin II and aldosterone. Increased angiotensin II levels promote vasoconstriction and blood pressure elevation. Concurrently, higher aldosterone levels stimulate sodium and water reabsorption in the kidneys,...
01:30Inhibitors of Viral Protein Synthesis
Protein synthesis is indispensable for viral replication, as viruses lack the cellular machinery required for this process and must hijack the host's translational apparatus. In response, host cells deploy a critical innate immune defense involving interferons, specialized cytokines that play a central role in inhibiting viral propagation.Upon viral detection, infected cells release interferons that bind to receptors on adjacent uninfected cells, activating the JAK-STAT signaling pathway and...
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
01:20Desensitization and Tachyphylaxis
Tachyphylaxis is described as a rapid decrease in response to a drug after repeated or continuous administration of the same drug dose. It is a phenomenon where the body becomes less responsive to a particular substance or intervention over time, requiring higher doses or stronger interventions to achieve the same effect. It results from adaptive changes in the body's receptors, signaling pathways, or physiological processes that occur in response to prolonged exposure to a stimulus.
Several...
Several...
01:15Impact of Pharmacokinetic–Pharmacodynamic Models: Regulatory Decisions
PK–PD modeling has significantly influenced FDA regulatory decisions, particularly drug approval, dosage optimization, and labeling. These models integrate pharmacokinetics (PK) and pharmacodynamics (PD) to predict drug behavior and effects, aiding in optimizing dosing regimens and enhancing the probability of clinical trial success.One notable example is Nesiritide (Natrecor®), a recombinant human brain natriuretic peptide for treating acute decompensated congestive heart failure (CHF).
01:23Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists
Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...